Insider Selling: Andreas Wicki Sells 64,400 Shares of Pacira Pharmaceuticals Stock (PCRX)
Pacira Pharmaceuticals (NASDAQ:PCRX) Director Andreas Wicki unloaded 64,400 shares of the stock on the open market in a transaction dated Tuesday, May 27th. The stock was sold at an average price of $77.93, for a total value of $5,018,692.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Pacira Pharmaceuticals (NASDAQ:PCRX) traded up 0.35% during mid-day trading on Wednesday, hitting $78.45. The stock had a trading volume of 290,621 shares. Pacira Pharmaceuticals has a 52 week low of $26.72 and a 52 week high of $83.41. The stock’s 50-day moving average is $71.94 and its 200-day moving average is $65.15. The company’s market cap is $2.797 billion.
Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its quarterly earnings results on Thursday, May 1st. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.13. The company had revenue of $36.70 million for the quarter, compared to the consensus estimate of $35.40 million. The company’s revenue for the quarter was up 216.4% on a year-over-year basis. Analysts expect that Pacira Pharmaceuticals will post $-0.63 EPS for the current fiscal year.
A number of research firms have recently commented on PCRX. Analysts at Jefferies Group reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Thursday, May 15th. They now have a $81.00 price target on the stock. Seven research analysts have rated the stock with a buy rating, Pacira Pharmaceuticals has a consensus rating of “Buy” and an average price target of $75.40.
Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.